124 related articles for article (PubMed ID: 22580307)
1. Construction of novel bifunctional chimeric proteins possessing antitumor and thrombolytic activities.
Hui J; Dai Y; Bian Y; Li H; Cui X; Yu X; You S; Hu F
J Microbiol Biotechnol; 2012 Jul; 22(7):894-901. PubMed ID: 22580307
[TBL] [Abstract][Full Text] [Related]
2. Construction of novel chimeric proteins through the truncation of SEC2 and Sak from Staphylococcus aureus.
Hui J; Yu XJ; Cui XJ; Mu T; Lin JS; Ni P; Li H; You S; Hu FQ
Biosci Biotechnol Biochem; 2014; 78(9):1514-21. PubMed ID: 25209498
[TBL] [Abstract][Full Text] [Related]
3. A new recombinant thrombolytic and antithrombotic agent with higher fibrin affinity - a staphylokinase variant. An in-vivo study.
Szemraj J; Stankiewicz A; Rozmyslowicz-Szermińska W; Mogielnicki A; Gromotowicz A; Buczko W; Oszajca K; Bartkowiak J; Chabielska E
Thromb Haemost; 2007 Jun; 97(6):1037-45. PubMed ID: 17549308
[TBL] [Abstract][Full Text] [Related]
4. New derivative of staphylokinase SAK-RGD-K2-Hirul exerts thrombolytic effects in the arterial thrombosis model in rats.
Szemraj J; Zakrzeska A; Brown G; Stankiewicz A; Gromotowicz A; Grędziński T; Chabielska E
Pharmacol Rep; 2011; 63(5):1169-79. PubMed ID: 22180359
[TBL] [Abstract][Full Text] [Related]
5. Fusion proteins with anticoagulant and fibrinolytic properties: functional studies and structural considerations.
Icke C; Schlott B; Ohlenschläger O; Hartmann M; Gührs KH; Glusa E
Mol Pharmacol; 2002 Aug; 62(2):203-9. PubMed ID: 12130670
[TBL] [Abstract][Full Text] [Related]
6. Expression and characterization of bifunctional fusion proteins possessing antitumor and thrombolytic function for targeting therapy.
Hui J; Lin JS; Hu Y; Li H; Hu FQ
Biotechnol Appl Biochem; 2016; 63(2):170-7. PubMed ID: 25644017
[TBL] [Abstract][Full Text] [Related]
7. Construction of a novel Staphylokinase (SAK) mutant with low immunogenicity and its evaluation in rhesus monkey.
Wang M; Chen Y; Fu W; Zou M; Wang Y; Xing W; Wang J; Xu D
Int J Biol Macromol; 2020 Mar; 146():781-789. PubMed ID: 31730959
[TBL] [Abstract][Full Text] [Related]
8. Locally activity-released bifunctional fusion protein enhances antithrombosis and alleviates bleeding risk.
Shi B; Yu A; Liu Y; Li J; Jin J; Dong C; Wu C
J Thromb Thrombolysis; 2007 Dec; 24(3):283-92. PubMed ID: 17487572
[TBL] [Abstract][Full Text] [Related]
9. Construction and characterization of a novel staphylokinase variant with thrombin-inhibitory activity.
Wang M; Wang Y; Wang J; Zou M; Liu S; Xu T; Cai X; Wu C; Wang J; Xu D
Biotechnol Lett; 2009 Dec; 31(12):1923-7. PubMed ID: 19685208
[TBL] [Abstract][Full Text] [Related]
10. Integration of VEK-30 peptide enhances fibrinolytic properties of staphylokinase.
Bhando T; Singh S; Hade MD; Kaur J; Dikshit KL
Biotechnol Appl Biochem; 2021 Apr; 68(2):213-220. PubMed ID: 32233032
[TBL] [Abstract][Full Text] [Related]
11. Novel recombinant thrombolytic and antithrombotic staphylokinase variants with an RGD motif at their N-termini.
He J; Di J; Xu R; Zhao B
Biotechnol Appl Biochem; 2008 May; 50(Pt 1):17-23. PubMed ID: 18039183
[TBL] [Abstract][Full Text] [Related]
12. Transcytosis, Antitumor Activity and Toxicity of Staphylococcal Enterotoxin C2 as an Oral Administration Protein Drug.
Zhao W; Li Y; Liu W; Ding D; Xu Y; Pan L; Chen S
Toxins (Basel); 2016 Jun; 8(6):. PubMed ID: 27322320
[TBL] [Abstract][Full Text] [Related]
13. The construction of a bifunctional fusion protein consisting of SEC2 and EGFP.
Liu Y; Xu M; Li X; Sun J; Zhang C; Zhang H
Biotechnol Appl Biochem; 2014; 61(5):565-71. PubMed ID: 24397332
[TBL] [Abstract][Full Text] [Related]
14. Characterization of a novel bifunctional mutant of staphylokinase with platelet-targeted thrombolysis and antiplatelet aggregation activities.
Chen H; Mo W; Su H; Zhang Y; Song H
BMC Mol Biol; 2007 Oct; 8():88. PubMed ID: 17919340
[TBL] [Abstract][Full Text] [Related]
15. Refolding of a staphylokinase variant y1-Sak by reverse dilution.
He J; Wang G; Xu R; Feng J; Wang J; Su H; Song H
Appl Biochem Biotechnol; 2008 Oct; 151(1):29-41. PubMed ID: 18785020
[TBL] [Abstract][Full Text] [Related]
16. Staphylokinase-annexin XI chimera exhibited efficient in vitro thrombolytic activities.
Chiou JF; Woon MD; Cheng SN; Hsu CH; Cherng SC; Hsieh FK; Lin SM; Shiau CY
Biosci Biotechnol Biochem; 2007 May; 71(5):1122-9. PubMed ID: 17485856
[TBL] [Abstract][Full Text] [Related]
17. Thrombolytic efficacy of native recombinant staphylokinase on femoral artery thrombus of rabbits.
Li CJ; Huang J; Yang ZJ; Cao KJ
Acta Pharmacol Sin; 2007 Jan; 28(1):58-65. PubMed ID: 17184583
[TBL] [Abstract][Full Text] [Related]
18. Comparison of expression optimization of new derivative of staphylokinase (SAK-2RGD-TTI) with the rSAK.
Faraji H; Ramezani M; Mashkani B; Sadeghnia HR; Benhangi HM; Hosseini Teshnizi S; Soltani F
Biotechnol Prog; 2019 Jul; 35(4):e2819. PubMed ID: 30972956
[TBL] [Abstract][Full Text] [Related]
19. An engineered superantigen SEC2 exhibits promising antitumor activity and low toxicity.
Xu M; Wang X; Cai Y; Zhang H; Yang H; Liu C; Zhang C
Cancer Immunol Immunother; 2011 May; 60(5):705-13. PubMed ID: 21331815
[TBL] [Abstract][Full Text] [Related]
20. Inhibiting tumor-cell growth by novel truncated staphylococcal enterotoxin C2 mutant.
Hui J; Xiao F; Li H; Cui X; Liu H; Hu F
Sheng Wu Gong Cheng Xue Bao; 2011 Jun; 27(6):891-9. PubMed ID: 22034818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
